Biogen Idec Offers Profits, Buybacks, But Mixed Messages on Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech says its closely-watched MS drug Tysabri helped drive better than expected profits, but admitted it might need a new safety label.